203 related articles for article (PubMed ID: 34612174)
1. L-asparaginase from
Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Saeed H; Hemida A; Abdel-Fattah M; Eldoksh A; Shalaby M; Nematalla H; El-Nikhely N; Elkewedi M
Protein Expr Purif; 2021 May; 181():105820. PubMed ID: 33440252
[TBL] [Abstract][Full Text] [Related]
3. L-asparaginase production review: bioprocess design and biochemical characteristics.
Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
[TBL] [Abstract][Full Text] [Related]
4. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
5. Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Saeed H; Hemida A; El-Nikhely N; Abdel-Fattah M; Shalaby M; Hussein A; Eldoksh A; Ataya F; Aly N; Labrou N; Nematalla H
Int J Biol Macromol; 2020 Aug; 156():812-828. PubMed ID: 32311402
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
7. Bacillus sonorensis L. Asparaginase: Cloning, Expression in E. coli and Characterization.
Aly N; El-Ahwany A; Ataya FS; Saeed H
Protein J; 2020 Dec; 39(6):717-729. PubMed ID: 33106988
[TBL] [Abstract][Full Text] [Related]
8. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
Kotzia GA; Labrou NE
J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804
[TBL] [Abstract][Full Text] [Related]
9. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
10. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
[TBL] [Abstract][Full Text] [Related]
11. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
[TBL] [Abstract][Full Text] [Related]
12. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
[TBL] [Abstract][Full Text] [Related]
13. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
14. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and characterization of asparaginase II from Saccharomyces cerevisiae in Escherichia coli.
Lopes W; Santos BAFD; Sampaio ALF; Gregório Alves Fontão AP; Nascimento HJ; Jurgilas PB; Torres FAG; Bon EPDS; Almeida RV; Ferrara MA
Protein Expr Purif; 2019 Jul; 159():21-26. PubMed ID: 30836141
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
17. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
Modi T; Gervais D
Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
[TBL] [Abstract][Full Text] [Related]
18. Biochemical characterization of glutaminase-free L-asparaginases from Himalayan Pseudomonas and Rahnella spp. for acrylamide mitigation.
Patial V; Kumar S; Joshi R; Singh D
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128576. PubMed ID: 38048933
[TBL] [Abstract][Full Text] [Related]
19. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Lanvers C; Vieira Pinheiro JP; Hempel G; Wuerthwein G; Boos J
Anal Biochem; 2002 Oct; 309(1):117-26. PubMed ID: 12381370
[TBL] [Abstract][Full Text] [Related]
20. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Maese L; Rizzari C; Coleman R; Power A; van der Sluis I; Rau RE
Pediatr Blood Cancer; 2021 Oct; 68(10):e29169. PubMed ID: 34105243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]